Current application of chimeric antigen receptor T cell immunotherapy and related laboratory examinations
10.3760/cma.j.cn114452-20220228-00102
- VernacularTitle:嵌合抗原受体-T细胞免疫治疗应用现状及相关实验室检查
- Author:
Zhiyuan LIU
1
;
Bo PANG
Author Information
1. 中国中医科学院广安门医院检验科，北京 100053
- Keywords:
Neoplasms;
Chimeric antigen receptor T cell;
Immunotherapy;
Clinical laboratory techniques
- From:
Chinese Journal of Laboratory Medicine
2022;45(8):871-874
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor (CAR)-T cell immunotherapy is a revolutionary advancement in cancer treatment, and is highly effective in treatment of B cell leukemia, lymphoma, and multiple myeloma. However, it has some deficiencies such as antigen escape, antigen heterogeneity, toxic and side effects, which also pose challenges for therapy of other hematological malignancies and solid tumors. Comprehensive and continuous laboratory monitoring before and after CAR-T cell immunotherapy plays an important role in early warning of toxic and side effects, as well as theraputic evaluation. In the future, new breakthroughs for tumor therapy. Should be focused on improving CAR-T cells design, enhancing their anti-tumor activity, and optimizing therapeutic regimen.
